Institute of Bioinformatics, International Technology Park, Bangalore, India.
Cancer Biol Ther. 2011 Sep 15;12(6):510-22. doi: 10.4161/cbt.12.6.16833.
Esophageal squamous cell carcinoma (ESCC) is among the top ten most frequent malignancies worldwide. In this study, our objective was to identify potential biomarkers for ESCC through a quantitative proteomic approach using the isobaric tags for relative and absolute quantitation (iTRAQ) approach. We compared the protein expression profiles of ESCC tumor tissues with the corresponding adjacent normal tissue from ten patients. LC-MS/MS analysis of strong cation exchange chromatography fractions was carried out on an Accurate Mass QTOF mass spectrometer, which led to the identification of 687 proteins. In all, 257 proteins were identified as differentially expressed in ESCC as compared to normal. We found several previously known protein biomarkers to be upregulated in ESCC including thrombospondin 1 (THBS1), periostin 1 (POSTN) and heat shock 70 kDa protein 9 (HSPA9) confirming the validity of our approach. In addition, several novel proteins that had not been reported previously were identified in our screen. These novel biomarker candidates included prosaposin (PSAP), plectin 1 (PLEC1) and protein disulfide isomerase A 4 (PDIA4) that were further validated to be overexpressed by immunohistochemical labeling using tissue microarrays. The success of our study shows that this mass spectrometric strategy can be applied to cancers in general to develop a panel of candidate biomarkers, which can then be validated by other techniques.
食管鳞状细胞癌(ESCC)是全球十大最常见恶性肿瘤之一。在这项研究中,我们的目的是通过使用相对和绝对定量同位素标记(iTRAQ)方法的定量蛋白质组学方法来鉴定 ESCC 的潜在生物标志物。我们比较了 10 名患者的 ESCC 肿瘤组织与相应的相邻正常组织的蛋白质表达谱。通过精确质量 QTOF 质谱仪对强阳离子交换色谱馏分进行了 LC-MS/MS 分析,鉴定出 687 种蛋白质。与正常组织相比,共有 257 种蛋白质被鉴定为 ESCC 中差异表达。我们发现几种先前已知的蛋白质生物标志物在 ESCC 中上调,包括血小板反应蛋白 1(THBS1)、骨膜蛋白 1(POSTN)和热休克 70 kDa 蛋白 9(HSPA9),证实了我们方法的有效性。此外,我们的筛选还鉴定出了一些以前未报道过的新型蛋白质。这些新的生物标志物候选物包括前载脂蛋白(PSAP)、网蛋白 1(PLEC1)和蛋白二硫键异构酶 A4(PDIA4),通过使用组织微阵列进行免疫组织化学标记进一步验证了它们的过表达。我们研究的成功表明,这种质谱策略可一般应用于癌症,以开发一组候选生物标志物,然后通过其他技术进行验证。